Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2023-10-08 Proxy Solicitation & In…
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Notice of General Meeting/Proxy Form 19 pages 978.2KB
Proxy Solicitation & Information Statement Classification · 95% confidence The document is titled 'Notice of General Meeting Explanatory Statement and Proxy Form' for Avecho Biotechnology Limited, detailing the date, time, and format of the General Meeting, instructions for voting, proxy appointments, and the agenda including resolutions to be voted on. It includes detailed procedural information for shareholders to participate and vote, including online voting instructions and proxy rules. The content is focused on the meeting logistics and the resolutions to be considered, rather than presenting financial results, audit opinions, or management discussions. The document is clearly a notice and explanatory statement for a shareholder meeting, which fits the category of Proxy Solicitation & Information Statement (PSI). It is not an Annual Report, Earnings Release, or Management Report, nor is it a voting results announcement or a regulatory filing. Therefore, the correct classification is PSI with high confidence.
2023-10-08 English
Application for quotation of securities - AVE 5 pages 25.8KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the number and type of securities to be quoted, issue dates, and related information. It references a previous Appendix 3B announcement about the issue of securities. The content focuses on the listing and quotation of new shares following a placement or issue. This is a capital market activity related to share issuance and quotation, not a financial report, earnings release, or management discussion. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length is 4242 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2023-09-06 English
Appendix 4D and Half-year Financial Report 23 pages 1.4MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Avecho Biotechnology Limited Appendix 4D Half-year report' and references the reporting period ended 30 June 2023. It contains detailed financial data including revenues, losses, cash flows, net assets, and a comprehensive directors' report. It also includes auditor's review report and consolidated financial statements such as profit or loss, financial position, changes in equity, and cash flows. The document discusses operational reviews, capital raising activities, and clinical trial progress, which are typical contents of an interim or half-year financial report. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is a full financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-30 English
Avecho raises further $6M for Phase III trial 4 pages 92.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 28 August 2023 regarding Avecho Biotechnology Limited conducting a $6 million placement to advance a Phase III clinical trial. It details the terms of the placement, including the number of shares issued, pricing, use of funds, and conditions such as shareholder approval. The document also includes an appendix describing the rights and liabilities attached to new options issued as part of the placement. There are no financial statements or comprehensive financial data presented, nor is this a full report like an annual or interim report. The content focuses on fundraising and capital structure changes through a placement of shares and options. Therefore, this document fits the category of a Capital/Financing Update (CAP). The document length is substantial (9988 characters), and it is not merely an announcement of a report publication or a certification. Hence, the classification is CAP with high confidence.
2023-08-27 English
Proposed issue of securities - AVE 6 pages 30.7KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Proposed issue of securities' and contains detailed information about a placement or other type of securities issue by Avecho Biotechnology Limited. It includes specifics such as the number and type of securities to be issued, issue price, proposed issue date, broker fees, and regulatory compliance with ASX Listing Rules. The content focuses on the announcement of a capital raising event rather than financial results, management discussion, or governance matters. There is no indication that this is a full financial report, audit, or earnings release. The document is a formal announcement of a financing activity, specifically a placement of shares and options. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (8960 characters) and detailed content support this classification with high confidence.
2023-08-27 English
Proposed issue of securities - AVE 7 pages 32.9KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Proposed issue of securities' and contains detailed information about a proposed placement or other type of securities issue by Avecho Biotechnology Limited. It includes specifics such as the number and type of securities to be issued, issue price, conditions including shareholder approval, fees to brokers, and the purpose of the issue. The document references compliance with ASX Listing Rules and includes an Appendix 3B form, which is a standard form used for notifying the ASX of new securities issues. There is no financial performance data, earnings information, or management discussion of results. The content is focused on capital raising and securities issuance details, which aligns with the category for updates on company fundraising or capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (9408 characters) and detailed content confirm it is not a mere announcement or regulatory filing but a substantive update on a capital raising event.
2023-08-27 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.